Log in - MyCLL

I am a UK HCP

This website is only intended for UK patients who have been prescribed Calquence^®▼(acalabrutinib). For UK members of the public, please visit Link https://www.astrazeneca.co.uk/

Please enter your details below:

Email address

Please provide a valid Email

Password

Please provide a valid password

Remember Me

Forgot your password?

Forgot your password?

Please enter the email that you used to join MyCLL and we'll send you an email with instructions how to reset your password.

Email address

This is not a valid email address

VVPM ID: GB-69481 Date of Prep: September 2025

This website is only intended for UK patients who have been prescribed Calquence^®▼ (acalabrutinib), which is used for the treatment of adults with chronic lymphocytic leukaemia (CLL). It does not replace the Patient Information Leaflet, which you can find in the carton containing your medicine and which you should read alongside this information. If you have any questions about your treatment, talk to your healthcare team or refer to the Patient Information Leaflet.

If you experience side effects with Calquence (acalabrutinib), talk to your Healthcare Professional. This includes any possible side effects not listed in the information leaflet that comes in the pack. You can report side effects via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/ (This link will take you to a website not owned by AstraZeneca. AstraZeneca provide this link as a service to our site visitors. AstraZeneca are not responsible for the content or privacy/legal policies of any third party websites). Side effects can also be reported to AstraZeneca on https://contactAZmedical.astrazeneca.com. By reporting side effects you can help provide more information on the safety of this medication.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk/ (This link will take you to a website not owned by AstraZeneca. AstraZeneca provide this link as a service to our site visitors. AstraZeneca are not responsible for the content or privacy/legal policies of any third party websites) for how to report side effects.

MyCLL is a patient support programme initiated, managed and fully funded by AstraZeneca UK. The information in this programme does not replace medical advice. If you have any questions, please speak to your healthcare team.

Privacy Notice
Terms and Conditions
Cookie Policy
Contact Us

Calquence^®▼ (acalabrutinib) is a registered trademark of the AstraZeneca group of companies
©2025 AstraZeneca All rights reserved.